학술논문
Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
Document Type
Journal
Author
Chaparro, M.; Donday, M. Garcia; Riestra, S.; Lucendo, A. J.; Benitez, J. M.; Navarro-Llavat, M.; Barrio, J.; Morales-Alvarado, V. J.; Rivero, M.; Busquets, D.; Carnerero, E. Leo; Ochoa, O. Merino; Castillejo, O. Nantes; Navarro, P.; Van Domselaar, M.; Casbas, A. Gutierrez; Alonso-Abreu, I.; Mejuto, R.; Salazar, L. Fernandez; Iborra, M.; Martin-Arranz, M. D.; Pineda, R.; Sampedro, M. J.; Nilsson, K. Serra; Assakali, A. Bouhmidi; Batista, L.; Villafranca, C. Munoz; Rodriguez-Lago, I.; Santos, D. S. Ceballos; Guerra, I.; Manosa, M.; Jimenez, I. Marin; Mendoza, I. Vera; Acosta, M. Barreiro-De; Domenech, E.; Esteve, M.; Garcia-Sanchez, V.; Nos, P.; Panes, J.; Gisbert, J. P.; Behalf Exit Study Grp Geteccu
Source
Subject
Language
English
ISSN
18764479